Europe Insulin Infusion Pumps Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 559.05 Million |
| Market Size (2029) | USD 675.26 Million |
| CAGR (2024 - 2029) | 3.85 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Insulin Infusion Pumps Market Analysis
The Europe Insulin Infusion Pumps Market size is estimated at USD 559.05 million in 2024, and is expected to reach USD 675.26 million by 2029, growing at a CAGR of 3.85% during the forecast period (2024-2029).
Over the past few years, Europe has observed a significant rise in its diabetic population, mirroring worldwide trends. Factors such as an aging demographic, shifts in lifestyle choices, and genetic factors have all played a role in the increasing prevalence of diabetes throughout Europe.
This surge affects both type 1 and type 2 diabetes, leading to a greater need for innovative technologies to effectively control the condition. An insulin pump (also known as continuous subcutaneous insulin therapy) is a medical device used for the administration of insulin in the treatment of diabetes. Insulin pumps make it possible to deliver continuous infusion amounts of insulin at regular intervals. This is predicted to result in long-term cost savings relative to multiple daily injections.
A conventional insulin pump includes the pump (including controls, a processing module, and batteries), a disposable reservoir for insulin (inside the pump), and a disposable infusion set, including a cannula for subcutaneous (under the skin) insertion and a tubing system to connect the insulin reservoir to the cannula. The configuration of the device may vary depending on the design. However, the application of infusion pumps across the world is increasing significantly.
Europe Insulin Infusion Pumps Market Trends
Insulin Pump Monitors Hold Largest Market Share
Countries in Europe are facing a high burden of diabetes expenditures. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to the same source, 21,600 children are added to the type-1 diabetic population every year.
These figures indicate that approximately 9% of the total healthcare expenditure in Europe is spent on diabetes. For patients relying on insulin pumps or multiple daily injections (MDI), CGM systems are an effective tool. They help in the improvement of glycemic balance without aggravating the danger of severe hypoglycemia.
In Europe, a variety of insulin pumps are available. Conventional insulin pumps have an insulin reservoir (or container) and a pumping mechanism attached to the body with tubing and an infusion set. Other insulin patch pumps are worn directly on the body and have a reservoir, pumping mechanism, and infusion set inside a small case. A separate device that allows for the programming of insulin delivery from the patch controls patch pumps wirelessly. Most insurance companies in Europe cover insulin pump therapy with variable out-of-pocket expenses.
The technology associated with insulin pumps combines glucose monitoring using CGM with advanced algorithms to predict low glucose and suspend insulin delivery. The technological innovation in the insulin pump market is likely to drive the market during the forecast period.
Germany Holds the Highest Market Share
The German Center for Diabetes Research (DZD) conducts extensive scientific research to develop effective prevention and treatment measures to prevent the emergence or progression of diabetes. Around 11% of the people living in Germany have private health insurance. Only people who fulfill certain criteria can have private health insurance. For example, the gross income of the person seeking insurance must have been above a certain threshold for at least one year. The developments in the insulin infusion pump reimbursement field are expected to bolster the adoption of insulin infusion pumps in Germany.
At least 7.2 percent of the population in Germany currently has diabetes, the majority of which is type-2 diabetes, depending on the estimate. Over the next 20 years, there can be a huge rise in the number of diabetics. Up to 12 million individuals in Germany could have type-2 diabetes in 20 years, according to researchers from the Robert Koch Institute (RKI) in Berlin and the German Diabetes Center (DDZ) in Düsseldorf. From 2015 to 2040, this is expected to represent an increase of up to 77%.
The DDZ scientists and their colleagues from the RKI published for the first time comprehensive projections of the future number of type-2 diabetes cases in Germany for all age groups based on the data of approximately 65 million subscribers to the German statutory health insurance and the Federal Statistical Office. They factored in current developments regarding newly diagnosed cases, rising life expectancy, and declining mortality rates as a result of medical advancements while calculating the development of case numbers between 2015 and 2040.
Europe Insulin Infusion Pumps Industry Overview
The new technologies in insulin infusion pump devices have driven the market study. Animas had to exit the insulin pump market due to rising competition. Medtronic is the market leader and is expected to maintain its position during the forecast period.
Europe Insulin Infusion Pumps Market Leaders
-
Medtronic
-
Roche
-
Ypsomed
-
Insulet
-
Tandem
*Disclaimer: Major Players sorted in no particular order
Europe Insulin Infusion Pumps Market News
- January 2024: Medtronic has obtained European approval to merge its most recent automated insulin pump with its latest glucose sensor, marking a significant milestone for the company. The MiniMed 780G pump and the Simplera Sync system, referred to as a disposable, comprehensive blood sugar sensor, are now covered by the CE mark. This innovative sensor can be effortlessly inserted under the skin in less than 10 seconds, eliminating the need for fingersticks.
- September 2022: Insulet announced that the Omnipod 5 system received CE mark clearance, making it available throughout the European Union. It's cleared for use by adults and children aged two and older with type-1 diabetes.
Europe Insulin Infusion Pumps Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Insulin Infusion Pump
- 5.1.1 Insulin Pump Devices
- 5.1.2 Insulin Infusion Sets
- 5.1.3 Reservoirs
-
5.2 Geography
- 5.2.1 France
- 5.2.2 Germany
- 5.2.3 Italy
- 5.2.4 Spain
- 5.2.5 United Kingdom
- 5.2.6 Russia
- 5.2.7 Rest of Europe
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Medtronic
- 7.1.2 Insulet
- 7.1.3 Roche
- 7.1.4 Animas
- 7.1.5 Tandem
- 7.1.6 Ypsomed
- 7.1.7 Cellnovo
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Roche
- 7.2.2 Animas
- 7.2.3 Medtronic
- 7.2.4 Other Company Share Analyses
8. MARKET OPPORTUNITES AND FUTURE TRENDS
Europe Insulin Infusion Pumps Industry Segmentation
An insulin pump might be a pleasant relief for diabetics who are sick of injecting themselves. A small, computerized device called an insulin pump can give insulin in one of two ways: either as a steady, measured, and continuous doze (known as "basal" insulin) or, at your request, as a surge ("bolus") doze just before meals. The European insulin infusion pump market is set to witness a CAGR of more than 4% during the forecast period. The European insulin infusion pump market is segmented by components and geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Insulin Infusion Pump | Insulin Pump Devices |
| Insulin Infusion Sets | |
| Reservoirs | |
| Geography | France |
| Germany | |
| Italy | |
| Spain | |
| United Kingdom | |
| Russia | |
| Rest of Europe |
Europe Insulin Infusion Pumps Market Research FAQs
How big is the Europe Insulin Infusion Pumps Market?
The Europe Insulin Infusion Pumps Market size is expected to reach USD 559.05 million in 2024 and grow at a CAGR of 3.85% to reach USD 675.26 million by 2029.
What is the current Europe Insulin Infusion Pumps Market size?
In 2024, the Europe Insulin Infusion Pumps Market size is expected to reach USD 559.05 million.
Who are the key players in Europe Insulin Infusion Pumps Market?
Medtronic, Roche, Ypsomed, Insulet and Tandem are the major companies operating in the Europe Insulin Infusion Pumps Market.
What years does this Europe Insulin Infusion Pumps Market cover, and what was the market size in 2023?
In 2023, the Europe Insulin Infusion Pumps Market size was estimated at USD 537.53 million. The report covers the Europe Insulin Infusion Pumps Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Insulin Infusion Pumps Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Insulin Infusion Pumps Industry Report
Statistics for the 2024 Europe Insulin Infusion Pumps market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Insulin Infusion Pumps analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
